SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes

J Nikolich-Zugich, KS Knox, CT Rios, B Natt… - Geroscience, 2020 - Springer
Abstract SARS-CoV-2 virus, the causative agent of the coronavirus infectious disease-19
(COVID-19), is taking the globe by storm, approaching 500,000 confirmed cases and over …

[PDF][PDF] Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)

B Shanmugaraj, K Siriwattananon… - Asian Pacific journal …, 2020 - apjai-journal.org
Last decade witnessed the outbreak of many life-threatening human pathogens including
Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS …

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

J Lan, J Ge, J Yu, S Shan, H Zhou, S Fan, Q Zhang… - nature, 2020 - nature.com
A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-
2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from …

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

R Bos, L Rutten, JEM van der Lubbe, MJG Bakkers… - npj Vaccines, 2020 - nature.com
Abstract Development of effective preventative interventions against SARS-CoV-2, the
etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS …

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

M Yuan, NC Wu, X Zhu, CCD Lee, RTY So, H Lv… - Science, 2020 - science.org
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome–coronavirus 2 (SARS-CoV-2) has now become a pandemic, but there is currently …

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Z Lv, YQ Deng, Q Ye, L Cao, CY Sun, C Fan, W Huang… - Science, 2020 - science.org
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …

[HTML][HTML] Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

G Zhou, Q Zhao - International Journal of Biological Sciences, 2020 - ncbi.nlm.nih.gov
A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated
respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the …

Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana

K Rattanapisit, B Shanmugaraj, S Manopwisedjaroen… - Scientific reports, 2020 - nature.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the
ongoing global outbreak of coronavirus disease (COVID-19) which is a significant threat to …

[HTML][HTML] Monoclonal antibody as a potential anti-COVID-19

L Jahanshahlu, N Rezaei - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) is expanding rapidly, which made it as one
of top priorities for scientists to develop novel treatment strategies. Researchers are racing to …

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

F Yu, R Xiang, X Deng, L Wang, Z Yu, S Tian… - … and Targeted Therapy, 2020 - nature.com
The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019
(COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe …